Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12206737 | 0.86 | TSHR (0.55) | TSHRSMN1; SMN2USP2RECQLPKM | |
| SCHEMBL10364035 | 0.85 | ALDH1A1 (0.41) | TSHRSMN1; SMN2RECQLPOLBCYP1A2 | |
| SCHEMBL296555 | 0.84 | TSHR (0.53) | TSHRSMN1; SMN2USP2RECQLPKM | |
| SCHEMBL17894913 | 0.84 | TSHR (0.53) | TSHRSMN1; SMN2USP2RECQLPKM | |
| SCHEMBL28738104 | 0.82 | TSHR (0.52) | TSHRSMN1; SMN2USP2RECQLPKM | |
| SCHEMBL21070421 | 0.82 | TSHR (0.52) | TSHRSMN1; SMN2USP2RECQLPKM | |
| SCHEMBL10364264 | 0.82 | TSHR (0.56) | TSHRSMN1; SMN2USP2RECQLPOLB | |
| SCHEMBL10624505 | 0.81 | TSHR (0.51) | TSHRSMN1; SMN2USP2RECQLPKM | |
| SCHEMBL15593785 | 0.81 | ALDH1A1 (0.41) | TSHRSMN1; SMN2POLBCYP1A2CYP2C9 | |
| SCHEMBL17212822 | 0.79 | TSHR (0.49) | TSHRSMN1; SMN2USP2RECQLPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109608436-A | Substituted Methylformyl reagent and the method for improving compound physical chemistry and/or pharmacokinetic property using the reagent | 斯法尔制药私人有限公司 | 2019-04-12 | — | — | CN | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | claimed |
| CN-103607888-A | Substituted methyl formyl reagents and methods of using the same to improve physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PRIVATE LTD | 2014-02-26 | — | — | CN | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| CN-118451064-A | Process for preparing derivatives of substituted morpholines | 苏佩努斯制药公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| WO-2022152705-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-07-21 | — | — | WO | disclosed |
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-7544706-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| EP-0104984-B1 | VINYLCARBAMIC ACID ESTERS AND THEIR PREPARATION | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1990-05-16 | — | — | EP | disclosed |
| US-4772695-A | DEHYDROHALOGENATION, INSECTICIDES | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1988-09-20 | — | — | US | disclosed |
| EP-0104984-A2 | Vinylcarbamic acid esters and their preparation | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | TSHR 3443/4885SMN1; SMN2 1394/4885USP2 2825/4885 |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | TSHR 2897/4885SMN1; SMN2 1578/4885USP2 3299/4885 |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | TPMT, BHMT2, PFAS | TSHR 3151/4885SMN1; SMN2 2629/4885USP2 3584/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | TSHR 3443/4885SMN1; SMN2 1394/4885USP2 2825/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | TSHR 3443/4885SMN1; SMN2 1394/4885USP2 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.